Stockreport

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal ...

Neurocrine Biosciences, Inc.  (NBIX) 
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: neurocrine.com/about-us/webcasts-presentations
PDF Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort ® /Efmody ® ) in Adrenal Insufficiency Phase 3 Extension Study Data for Modifie [Read more]